Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;27(7):409-14.
doi: 10.1007/s10815-010-9433-4. Epub 2010 May 20.

Maternal antimullerian hormone levels do not predict fetal aneuploidy

Beth J Plante  1 , Carmen Beamon, Colleen L Schmitt, Julie S Moldenhauer, Anne Z Steiner
Affiliations

Maternal antimullerian hormone levels do not predict fetal aneuploidy

Beth J Plante et al. J Assist Reprod Genet. 2010 Jul.

Abstract

Purpose: To determine if diminished ovarian reserve (measured by maternal antimullerian hormone (AMH) levels), is associated with fetal aneuploidy (determined by prenatal karyotype).

Methods: This case-control study included 213 women with singleton pregnancies who underwent both serum aneuploidy screening and invasive prenatal diagnosis. 18 patients carrying an aneuploid fetus served as cases and the remaining 195 women with a euploid fetus were controls. Serum AMH was measured using two assays: AMHbc (Beckman-Coulter) and AMHdsl (Diagnostic Systems Laboratories). Karyotypes were determined by chorionic villus sampling or amniocentesis.

Results: AMHbc levels did not differ between women with an aneuploid fetus and women with a euploid fetus (p = 0.46) and did not predict aneuploidy (ROC Area = 0.57). Additionally, AMHbc values declined significantly with advancing gestational age.

Conclusions: Maternal AMH does not appear to be a marker of fetal aneuploidy in ongoing pregnancies. Contrary to previous reports, we found a significant decline in maternal AMH levels with advancing gestational age.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
AMHbc values declined significantly with advancing gestational age (p < 0.001)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve—should we perform tests of ovarian reserve routinely? Hum Reprod. 2006;21(11):2729–35. doi: 10.1093/humrep/del188. - DOI - PubMed
    1. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9. doi: 10.1016/j.fertnstert.2004.03.061. - DOI - PubMed
    1. Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007;88(3):539–46. doi: 10.1016/j.fertnstert.2007.02.014. - DOI - PubMed
    1. Josso N, Picard JY, Rey R, Clemente N. Testicular anti-Mullerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev. 2006;3(4):347–58. - PubMed
    1. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2008 Nov 29. - PubMed

Publication types

Substances

LinkOut - more resources